Latest news with #PiramalPharma
Business Standard
19 hours ago
- Business
- Business Standard
Piramal Pharma reports consolidated net loss of Rs 81.70 crore in the June 2025 quarter
Sales decline 0.89% to Rs 1933.71 crore Net Loss of Piramal Pharma reported to Rs 81.70 crore in the quarter ended June 2025 as against net loss of Rs 88.64 crore during the previous quarter ended June 2024. Sales declined 0.89% to Rs 1933.71 crore in the quarter ended June 2025 as against Rs 1951.14 crore during the previous quarter ended June 2024. Particulars Quarter Ended Jun. 2025 Jun. 2024 % Var. Sales 1933.711951.14 -1 OPM % 5.5210.48 - PBDT 97.52139.47 -30 PBT -99.76-45.08 -121 NP -81.70-88.64 8
Business Standard
19 hours ago
- Business
- Business Standard
Piramal Pharma posts loss of Rs 82 crore in Q1; EBITDA margin declines to 9%
Piramal Pharma has reported a consolidated net loss of Rs 82 crore in Q1 FY26 as against a net loss of Rs 89 crore recorded in Q1 FY25. Revenue from operations for the period under review declined by 1% year-over-year (YoY) to Rs 1,934 crore. EBITDA fell by 26% to Rs 165 crore in Q1 FY26 from Rs 224 crore in Q1 FY25. EBITDA margin for Q1 FY26 was 9% as against 11% in Q1 FY25, primarily impacted by inventory destocking. This was partly offset by improved profitability of the overseas facilities in the CDMO business. The company posted a pre-tax loss of Rs 79 crore in the June25 quarter as against a pre-tax loss of Rs 45 crore registered in the same period last year. Nandini Piramal, chairperson, Piramal Pharma, said: Excluding the impact of destocking in one large on-patent commercial product, our CDMO business delivered mid-teen revenue growth during the quarter accompanied by improvement in EBITDA margin, especially at our overseas sites. Growth in our CHG business is also expected to pick up for the remaining part of the year given the timing of some of the institutional orders. Our consumer business delivered healthy growth, in-line with our expectations, driven by power brands and e commerce sales. Withstanding the near-term challenges, we believe we are on track to achieve our FY2030 aspirations of becoming a $2 billion revenue company with 25% EBITDA margin and high-teen ROCE. Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. The scrip tumbled 4.80% to currently trade at Rs 194.55 on the BSE.
Business Standard
22-07-2025
- Business
- Business Standard
Piramal Pharma to sell its decommissioned unit in MIDC, Thane for Rs 8.50 cr
Piramal Pharma announced that the Administrative Committee of the Board, at its meeting held today, has approved execution of a sale deed and ancillary definitive agreements with Global Pharma (Buyer) for the sale of decommissioned unit located at A-159, MIDC, Wagle Industrial Estate, Thane West 400604 for a proposed consideration of approximately Rs. 8.50 core plus applicable taxes. The transaction is expected to conclude within 90 days, subject to fulfilment of conditions as described in the sale deed. The company added, "We reiterate that the unit is decommissioned and contributed Nil to the Company's turnover, income, and net worth in the last financial year. Accordingly, sale will have no impact on Company operations."
&w=3840&q=100)
Business Standard
04-07-2025
- Business
- Business Standard
Stocks to Watch Today, July 4: Piramal Pharma, RIL, Bajaj Fin, BoB, IEX
Stocks to Watch Today, Friday, July 4, 2025: Stock markets today could open flat-to-positive with GIFT Nifty futures trading 19 points higher at 25,528 at 6:55 AM. Globally, Asia-Pacific markets were mixed Friday morning after Wall Street gained on a better-than-expected jobs report eased investors' concerns of a slowdown in the US economy. Overnight, the Dow Jones Industrial Average advanced 0.77 per cent, the S&P 500 added 0.83 per cent, and Nasdaq gained 1.02 per cent. Meanwhile, here is a list of stocks to watch today: Piramal Pharma share price: According to reports, private equity firm Carlyle Group could offload up to 10 per cent stake in Piramal Pharma through block deals today. The sale could amount to ₹2,600-2,700 crore. Emcure Pharmaceuticals share price: BC Investments IV (Bain Capital) could sell a 2.4-per cent equity stake in the company via block deals, reports suggested. Bajaj Finance share price: Sharing an update on the April-June quarter (Q1FY26) business performance, Bajaj Finance said its new loans booked grew by 23 per cent year-on-year (Y-o-Y) to 13.49 million as compared to 10.97 million in Q1FY25. This took the total customer count to 106.51 million as compared to 88.11 million Y-o-Y. The NBFC added 4.69 million customers in Q1FY26. Further, Bajaj Finance's deposits book grew by 15 per cent to approximately ₹72,100 crore as of June 30, 2025, as compared to ₹62,774 crore as of June 30, under management (AUM) grew by 25 per cent to approximately ₹441,400 crore at the end of the quarter. Bank of Baroda share price: Bank of Baroda said its Global Advances rose 12.63 per cent Y-o-Y to ₹12.07 trillion as in Q1FY26, while Domestic Advances increased 12.45 per cent to ₹9.91 trillion. Similarly, its Global Deposits jumped 9.13 per cent Y-o-Y to ₹14.36 trillion, and Domestic Deposits were up by 8.10 per cent to ₹12.04 trillion. Bandhan Bank share price: Bandhan Bank's Loans and Advances increased 6.4 per cent Y-o-Y, but fell 2.5 per cent Q-o-Q, to ₹133,635 crore at the end of June, 2025. Its Total Deposits, however, surged 16.1 per cent Y-o-Y and 2.3 per cent Q-o-Q to ₹154,664 crore. CASA deposits, however, declined around 6 per cent on a yearly basis and 12 per cent on quarterly basis. AWL Agri Business share price: AWL Agri Business, formerly known as Adani Wilmar, said the company experienced a challenging quarter due to muted consumer demand, strategic consolidation of regional rice operations, the winding down of G2G rice sales, and fluctuations in edible oil prices. This led to a 4-per cent Y-o-Y decline in overall Q1FY26 volume, dragged by the rice category. That said, revenue rose 21 per cent Y-o-Y, driven by higher edible oil realisations. Marico share price: The owner of 'Parachute' and 'Saffola Oils' said underlying volume growth in the India business continued to improve sequentially and reached multi-quarter high in Q1, driven by continuous scale up of new businesses. Further, the International business delivered high-teen growth in constant currency. "Consolidated revenue growth on a year-on-year basis stood in the low twenties, marking a strong start towards delivering double-digit growth on a full year basis, underpinned by the strengthening volume trajectory," Marico said. Indian Energy Exchange (IEX) share price: The company said it has achieved a traded volume of 10,852 MU in June 2025, marking 6.5 per cent Y-o-Y growth. Reliance Industries share price: RIL's retail arm, Reliance Retail Ventures Ltd (RRVL), has bought a strategic minority stake in UK-based FaceGym, a facial fitness and skincare brand. RBL Bank share price: RBL Bank's total deposits, in Q1FY26, grew by 11 per cent Y-o-Y and 2 per cent Q-o-Q to Rs 1,12,665 crore. The private lender's gross advances, meanwhile, were up 9 per cent Y-o-Y/2 per cent Q-o-Q to Rs 96,704 crore. Retail advances, RBL Bank said, were up by 7 perc cent Yo-Y- and 2 per cent Q-o-Q, while wholesale advances grew 13 per cent Y-o-Y and 3 per cent Q-o-Q for the quarter ended June 30. Vedanta share price: The Anil Agarwal-owned Vedanta said that the company saw record quarterly alumina production of 587 kt (up 36 per cent Q-o-Q) at the Lanjigarh Refinery. Moreover, Zinc India recorded its highest-ever Q1 mined metal production at 265 kt, up 1 per cent Y-o-Y, while Zinc International production rose 50 per cent Y-o-Y and 12 per cent Q-o-Q. Vedanta also saw record production of Ferro Chrome (up 150 per cent Q-o-Q), with best-ever Ore production (66 per cent Q-o-Q). Jindal Steel and Power share price: Sharing an update with the shareholders, Jindal Steel said the Government of Odisha has issued a Letter of Intent (LoI) to the company for the grant of a 50-year Mining Lease for the Roida-I Iron Ore and Manganese Block, located in Keonjhar District. The Roida-I Iron Ore and Manganese Block comes with an Environmental Clearance capacity of 3 Million Tonnes Per Annum (MTPA) and a mineral deposit of 126.05 Million Tonnes. Godavari Biorefineries share price: The small-cap company has won a patent in Europe for its anticancer molecule. The patent is validated in Spain, the UK, and as a Unitary Patent. One Mobikwik Systems share price: Mobikwik Securities Broking Private Limited (MSBPL), a wholly-owned subsidiary of One MobiKwik Systems, has received regulatory approval from the Securities and Exchange Board of India (Sebi) to act as a Stock Broker / Clearing Member. Bharat Forge share price: Kalyani Strategic Systems, a wholly-owned subsidiary of Bharat Forge, has incorporated a company, namely, Agneyastra Energetics Limited. This new wholly-owned subsidiary, will manufacture High Energy Explosives, Ammunition High Explosive Filling (Heavy & Medium Caliber), Manufacturing of Gun Propellants and Rocket Propellants, creating an end-to-end defence energetics capabilities.
&w=3840&q=100)
Business Standard
03-07-2025
- Business
- Business Standard
Carlyle Group may sell 10% stake in Piramal Pharma via block deals: Report
United States-based private equity firm Carlyle Group is planning to divest up to 10 per cent stake in Piramal Pharma through block deals, Moneycontrol reported on Thursday, citing sources. The sale could amount to ₹2,600-2,700 crore, the report added. Piramal Pharma sold 20 per cent of its stake to Carlyle Group in June 2020, in a deal worth ₹3,523 crore. According to stock exchange data, it held 18 per cent stake in the pharma firm as of March 31, 2025. Financial services firm Motilal Oswal has been roped in to facilitate the block deals, the report added. Piramal Pharma operates a diverse and global pharmaceutical business, providing a broad range of products and services. It includes Piramal Pharma Solutions (PPS), a fully integrated contract development and manufacturing organisation (CDMO); Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. Piramal Pharma Q4 result In the fourth quarter of FY25, Piramal Pharma posted a consolidated revenue from operations of ₹2,754 crore, marking an 8 per cent increase over the ₹2,552 crore recorded in the same quarter last year. The company's EBITDA (earnings before interest, tax, depreciation, and amortisation) also increased by 8 per cent year-on-year to ₹603 crore, up from ₹556 crore. Profit after tax (before exceptional items) came in at ₹154 crore, reflecting a 16 per cent rise compared to ₹132 crore in the corresponding period of the previous financial year. Shares of Piramal Pharma last traded at ₹202.4 apiece on the BSE at the close of the markets on Thursday.
